...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>American Journal of Obstetrics and Gynecology >Reproductive and oncologic outcomes after progestin therapy for endometrial complex atypical hyperplasia or carcinoma
【24h】

Reproductive and oncologic outcomes after progestin therapy for endometrial complex atypical hyperplasia or carcinoma

机译：孕激素治疗子宫内膜复杂非典型增生或癌后的生殖和肿瘤学结局

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Objectives This study evaluated fertility and oncological outcomes in women with complex atypical hyperplasia (CAH) or nonmyoinvasive grade 1 endometrioid endometrial carcinoma (EM) who desired fertility-sparing therapy. Study Design The retrospective cohort study included women younger than 45 years with CAH or EM who desired fertility-sparing treatment at our institution. Only patients for whom both oncological treatment and pregnancy outcomes were available were included. Statistical analyses were performed using a Fisher exact test, Pearson χ2 test, and Spearman rank correlation test, as appropriate. Results Seventy-five patients were identified, and 23 (13 CAH, 10 EM) met the inclusion criteria. All 23 patients had at least 1 prior pregnancy. Treatment was split between oral progesterone only (38.5% CAH, 40% EM), levonorgestrel intrauterine device only (30.8% CAH, 20% EM), and both (30.8% CAH, 40% EM). After a median follow-up of 13 months (range, 3-74 months), 9 patients (46.2% CAH, 30% EM, P =.39) had persistent/progressive disease. Eight patients (30.8% CAH, 40% EM, P =.69) ultimately had a hysterectomy, and 3 of these (13.0%) were found to have persistent/progressive disease. Median time from diagnosis to hysterectomy was 13 months (range, 4-56 months). Fourteen of the 23 patients utilized assisted reproductive techniques (60.9%); 12 underwent IVF and 2 chose a gestation carrier. Seven clinical intrauterine pregnancies (30.4%) resulting in 6 live births (26.1%) were found in the entire cohort. Conclusion Fertility-sparing treatment for CAH and grade 1 endometrial cancer is feasible with progestin therapy and leads to clinically meaningful rates of pregnancy in young women who desire fertility.
机译：目的这项研究评估了需要保育治疗的复杂非典型增生（CAH）或非子宫浸润性1级子宫内膜样子宫内膜癌（EM）妇女的生育力和肿瘤学结局。研究设计回顾性队列研究包括45岁以下患有CAH或EM的女性，他们希望在我们机构中保留生育能力。仅包括肿瘤治疗和妊娠结局均可用的患者。适当地使用Fisher精确检验，Pearsonχ2检验和Spearman等级相关检验进行统计分析。结果鉴定出75例患者，其中23例（13 CAH，10 EM）符合纳入标准。全部23例患者至少有1例在孕前。治疗分为口服黄体酮（38.5％CAH，40％EM），仅左炔诺孕酮宫内节育器（30.8％CAH，20％EM）和两者（30.8％CAH，40％EM）。在中位随访13个月（范围3-74个月）后，有9例患者（46.2％的CAH，30％的EM，P = 0.39）患有持续性/进行性疾病。最终有8例患者（30.8％CAH，40％EM，P = .69）进行了子宫切除术，其中3例（13.0％）被发现患有持续性/进行性疾病。从诊断到子宫切除术的中位时间为13个月（范围4-56个月）。 23例患者中有14例使用了辅助生殖技术（60.9％）。 12名接受了IVF，2名选择了妊娠载体。在整个队列中发现了7例临床子宫内妊娠（30.4％），导致6例活产（26.1％）。结论孕激素疗法可用于CAH和1级子宫内膜癌的保留生育能力的治疗是可行的，并能在希望生育的年轻妇女中产生具有临床意义的妊娠率。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号